Evidence map›Paper›PMID 19036131›Full record

ArticleBMC cancer2008

Effects of small interfering RNA targeting thymidylate synthase on survival of ACC3 cells from salivary adenoid cystic carcinoma.

Takashi Shirasaki, Shin-ichiro Maruya, Hiroki Mizukami, Seiji Kakehata, Hidekachi Kurotaki, Soroku Yagihashi, Hideichi Shinkawa

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Takashi ShirasakiDepartment of Otolaryngology, Hirosaki University School of Medicine, Hirosaki, Japan. taka-shira@nifty.com
Shin-ichiro Maruya
Hiroki Mizukami
Seiji Kakehata
Hidekachi Kurotaki
Soroku Yagihashi
Hideichi Shinkawa
Hirosaki University · JPOdawara Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThymidylate synthase (TS) is an important target for chemotherapeutic treatment of cancer and high expression of TS has been associated with poor prognosis or refractory disease in several cancers including colorectal and head and neck cancer. Although TS is known to regulate cell cycles and transcription factors, its potency as a therapeutic target has not been fully explored in adenoid cystic carcinoma (ACC).

methodsAn ACC cell line (ACC3) was transfected with siRNA targeting the TS gene and inhibition of cell growth and induction of apoptosis-associated molecules were evaluated in vitro. In addition, the in vivo effect of TS siRNA on tumor progression was assessed using a xenograft model.

resultsOur results demonstrated that ACC3 cells showed significantly higher TS expression than non-cancer cell lines and the induction of TS siRNA led to inhibition of cell proliferation. The effect was associated with an increase in p53, p21, and active caspase-3 and S-phase accumulation. We also found up-regulation of spermidine/spermine N1-acetyltransferase (SSAT), a polyamine metabolic enzyme. Furthermore, treatment with TS siRNA delivered by atelocollagen showed a significant cytostatic effect through the induction of apoptosis in a xenograft model.

conclusionTS may be an important therapeutic target and siRNA targeting TS may be of potential therapeutic value in ACC.

Indexed as

RNA InterferenceAcetyltransferasesAnimalsBlotting, WesternCarcinoma, Adenoid CysticCaspase 3Cell CycleCell Line, TumorCell SurvivalCyclin-Dependent Kinase Inhibitor p21FemaleGene ExpressionHumansMiceMice, NudeReverse Transcriptase Polymerase Chain ReactionAcetyltransferasesCASP3 protein, humanCaspase 3CDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21RNA, MessengerRNA, Small InterferingThymidylate SynthaseTumor Suppressor Protein p53

Identifiers

PMID19036131
PMCPMC2628925
OpenAlexW2163573587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.